Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293612 | 0.76 | KDM4E (0.34) | — | |
| SCHEMBL297505 | 0.75 | CYP3A4 (0.52) | MAPTTSHR | |
| SCHEMBL12076779 | 0.72 | CYP2E1 (0.44) | — | |
| SCHEMBL184324 | 0.71 | NOTUM (0.52) | MAPT | |
| SCHEMBL11674778 | 0.69 | TLR9 (0.39) | — | |
| SCHEMBL272488 | 0.68 | — | — | |
| SCHEMBL1586114 | 0.68 | CYP19A1 (0.31) | — | |
| SCHEMBL586173 | 0.67 | NOTUM (0.40) | — | |
| SCHEMBL8961761 | 0.67 | MAPT (0.31) | MAPT | |
| SCHEMBL1428273 | 0.67 | KDM4E (0.46) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-13 | — | — | US | claimed |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | claimed |
| EP-3093291-B1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-08 | — | — | EP | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | claimed |
| US-20170129901-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-11 | — | — | US | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| EP-3093291-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-11-16 | — | — | EP | claimed |
| EP-2491038-B1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-06 | — | — | EP | claimed |
| CN-102781942-B | Octahydro pyrrolo-[3,4-c] pyrroles is replaced as two of orexin receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-09-23 | — | — | CN | claimed |
| US-9079911-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | claimed |
| US-20140179697-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-26 | — | — | US | claimed |
| US-8653263-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA (BE) | 2014-02-18 | — | — | US | claimed |
| CN-102781942-A | Disubstituted octahy-dropyrrolo [3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV | 2012-11-14 | — | — | CN | claimed |
| EP-2491038-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-16 | — | — | US | claimed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | MAPT 4633/4885TSHR 3969/4885 |
| US-20170129901-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | MAPT 785/4885TSHR 344/4885 |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | MAPT 785/4885TSHR 344/4885 |
| US-20140179697-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | MAPT 785/4885TSHR 344/4885 |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | MAPT 785/4885TSHR 344/4885 |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | MAPT 785/4885TSHR 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.